Business
Annual Reports & Accounts & Notice of AGM
Annual Reports & Accounts & Notice of AGM.
About this update from Creo Medical Group Plc
[{"type":"text","content":"\n \nRNS Number : 8288Y Creo Medical Group PLC 13 May 2019 \n\nCreo Medical Group plc\n(\"Creo\" or \"the Company\")\n \nPosting of Annual Reports and Accounts\nNotice of Annual General Meeting\n \nCreo Medical Group plc (AIM: CREO), a medical device company focused on the emerging field of surgical endoscopy, announces that its Report and Accounts for the 18 month period ended 31 December 2018, together with its Notice of Annual General Meeting (\"AGM\") and a Form of Proxy, will be mailed out to shareholders today. \n \nThese documents are available on the Company's website: \nhttp://investors.creomedical.com/investors/reports-and-presentations/2019\n \nThe AGM will be held at 10 a.m. on Thursday 6 June 2019 at the Company's registered office, Creo House, Unit 2, Beaufort Park, Beaufort Park Way, Chepstow, Wales NP16 5UH. \n \n \n\n\n\nCreo Medical Group plc\n\n\n \n\n\n\n\nRichard Rees (CFO)\n\n\n+44 (0)129 160 6005 \n\n\n\n\n \n\n\n \n\n\n\n\nCenkos Securities\n\n\n+44 (0)20 7397 8900\n\n\n\n\nStephen Keys / Mark Connelly (NOMAD)\n\n\n \n\n\n\n\nMichael Johnson / Russell Kerr (Sales)\n\n\n \n\n\n\n\n \n\n\n \n\n\n\n\nWalbrook PR Ltd\n\n\nTel: +44 (0)20 7933 8780 or [email protected]\n\n\n\n\nPaul McManus\n\n\nMob: +44 (0)7980 541 893\n\n\n\n\nHelen Cresswell\n\n\nMob: +44 (0)7841 917 679\n\n\n\n \nAbout Creo Medical\n \nCreo Medical, founded in 2003, is a medical device company focused on the development and commercialisation of minimally invasive surgical devices, by bringing advanced energy to endoscopy. Creo's mission is to improve patient outcomes by applying microwave and RF energy to surgical endoscopy. Creo has developed CROMA, an electrosurgical advanced energy platform that combines bipolar radio frequency energy (for precise localised cutting) and microwave energy (for controlled coagulation). This technology provides clinicians with flexible, accurate and controlled surgical solutions.\n \nCreo's strategy is to bring its CROMA Advanced Energy platform to market through a suite of medical devices which Creo has designed, initially for the emerging field of GI therapeutic endoscopy, an area with high unmet needs. Creo intends to further develop the CROMA Advanced Energy platform for use on flexible and rigid endoscopic...